C12N 2740/13011
Gammaretrovirus
Official title: Gammaretrovirus, e.g. murine leukeamia virus
C12N2740/13011 (Gammaretrovirus) appears on 790 US grants and 939 published applications in this corpus.
Search patents in C12N- Granted patents
- 790
- Published applications
- 939
- Assignees
- 558
- Inventors
- 2,012
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 4 | 0 |
| 1990 | 4 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 6 | 0 |
| 1994 | 10 | 0 |
| 1995 | 11 | 0 |
| 1996 | 21 | 0 |
| 1997 | 43 | 0 |
| 1998 | 40 | 0 |
| 1999 | 45 | 0 |
| 2000 | 38 | 0 |
| 2001 | 49 | 8 |
| 2002 | 41 | 65 |
| 2003 | 27 | 57 |
| 2004 | 37 | 58 |
| 2005 | 18 | 45 |
| 2006 | 21 | 43 |
| 2007 | 15 | 33 |
| 2008 | 20 | 41 |
| 2009 | 20 | 23 |
| 2010 | 20 | 27 |
| 2011 | 8 | 22 |
| 2012 | 13 | 28 |
| 2013 | 9 | 16 |
| 2014 | 24 | 24 |
| 2015 | 15 | 13 |
| 2016 | 10 | 22 |
| 2017 | 14 | 18 |
| 2018 | 14 | 22 |
| 2019 | 19 | 33 |
| 2020 | 12 | 32 |
| 2021 | 18 | 52 |
| 2022 | 22 | 62 |
| 2023 | 21 | 48 |
| 2024 | 28 | 58 |
| 2025 | 34 | 51 |
| 2026 | 19 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/13041Use of virus, viral particle or viral elements as a vectorIndexing code557
- C12N 2740/13022New viral proteins or individual genes, new structural or functional aspects ofIndexing code240
- C12N 2740/13051Methods of production or purification of viral materialIndexing code137
- C12N 2740/13023Virus like particles [vlp]Indexing code51
- C12N 2740/13034Use of virus or viral component as vaccineIndexing code50
- C12N 2740/13061Methods of inactivation or attenuationIndexing code35
- C12N 2740/13032Use of virus as therapeutic agent, other than vaccineIndexing code18
- C12N 2740/13021Viruses as suchIndexing code13
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Damage-targeted treatments of disease16 Jun 2026US 12,653,906 B2
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Alternate detergents for viral inactivation9 Jun 2026US 12,649,907 B2Amgen Inc.
- Digital droplet based assay for detecting replication competent lentiviral vector1 Oct 2026US 2026/0297693 A1Sana Biotechnology, Inc.
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Expression construct10 Sep 2026US 2026/0265777 A1Lentitek Ltd
- Hla-a3-restricted t cell receptors against braf with v600e mutation20 Aug 2026US 2026/0242513 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Modified gamma delta t cells20 Aug 2026US 2026/0242730 A1Pointloma Biosciences, Inc.
Most cited
By later US patents
- In vivo introduction and expression of foreign genetic material in epithelial cells586US 4,980,286 AWhitehead Institute for Biomedical Research · 1990
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Introduction and expression of foreign genetic material in epithelial cells279US 4,868,116 AWhitehead Institute for Biomedical Research · 1989
- Retroviral gene transfer into diploid fibroblasts for gene therapy274US 5,219,740 AFred Hutchinson Cancer Research Center · 1993